Role of Metformin in Morbidity and Mortality Associated with Urinary Tract Infections in Patients with Type 2 Diabetes

• Published in: Journal of personalized medicine 2022-04, Vol.12 (5), p.702
• Main Authors: Yen, Fu-Shun, Wei, James Cheng-Chung, Shih, Ying-Hsiu, Pan, Wei-Lin, Hsu, Chih-Cheng, Hwu, Chii-Min
• Format: Article
• Language: English
• Subjects: Antibiotics; Cardiovascular disease; Chronic obstructive pulmonary disease; Death; Diabetes; Diabetes mellitus (non-insulin dependent); Drugs; Health insurance; Hepatitis; Hospitalization; Insulin; Metformin; Morbidity; Mortality; Patients; Pneumonia; Precision medicine; Sepsis; Statistical analysis; Urinary tract; Urinary tract diseases; Urinary tract infections; Urogenital system
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm12050702

We conducted this study to compare the morbidity and mortality associated with UTI and sepsis, between metformin users and nonusers in patients with diabetes. As such, 40,774 propensity score-matched metformin users and nonusers were identified from Taiwan's National Health Insurance Research Database, between 1 January 2000 and 31 December 2017. We adopted the Cox proportional hazards model with robust standard error estimates for comparing the risks of UTI, sepsis, and death due to UTI or sepsis, in patients with T2DM. Compared with the nonuse of metformin, the aHRs (95% CI) for metformin use in UTI, recurrent UTI, sepsis, and death due to UTI or sepsis were 1.06 (0.98, 1.15), 1.08 (0.97, 1.2), 1.01 (0.97, 1.06), and 0.58 (0.42, 0.8), respectively. The cumulative incidence of death due to UTI or sepsis was significantly lower in metformin users than in nonusers ( = 0.002). A longer cumulative duration of metformin use had a lower aHR in the risk of death due to UTI or sepsis than metformin nonuse. In patients with T2DM, metformin use showed no significant differences in the risks of UTI, recurrent UTI, or sepsis. However, it was associated with a lower risk of death due to UTI or sepsis than metformin nonuse.